Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Yiqi Guben Wan is a traditional Chinese medicine (TCM) formulation that has been investigated for its therapeutic potential, particularly in allergic asthma. Research indicates that it alleviates airway inflammation and remodeling by suppressing the TLR4/NF-κB signaling pathway, leading to reduced expression of key inflammatory mediators. Additionally, it has been shown to improve mitochondrial dysfunction, which contributes to its overall therapeutic effects in respiratory conditions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Yiqi Guben Wan.